Becton, Dickinson and Company Q2 Earnings Call Highlights

2 hours ago 4

MarketBeat

Sat, May 9, 2026 astatine 9:07 AM CDT 7 min read

Becton, Dickinson and Company logo

Becton, Dickinson and Company logo

Key Points

  • Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs

Becton, Dickinson and Company (NYSE:BDX) reported fiscal second-quarter gross and adjusted net up of its interior expectations, portion absorption raised its full-year adjusted net outlook and said maturation was broad-based crossed astir of the portfolio.

Chairman, Chief Executive Officer and President Tom Polen said gross was $4.7 billion, up 2.6% connected an FX-neutral basis, with adjusted operating borderline of 24.2% and adjusted diluted net per stock of $2.90. Polen said much than 90% of the company’s portfolio delivered mid-single-digit growth, portion known pressures from Alaris, vaccines and China weighed connected reported growth.

→ Light Speed Returns: Corning Cashes In connected NVIDIA Growth

  • Healthcare Stocks With astatine Least 30 Years of Dividend Increases

“The 4th demonstrates the expanding quality, breadth, and resilience of New BD,” Polen said, adding that the institution is focused connected 3 priorities: compete, innovate and deliver.

Growth Platforms Offset Focused Headwinds

Polen said BD delivered double-digit maturation successful respective cardinal platforms, including biologic cause delivery, precocious diligent monitoring, PureWick and precocious insubstantial regeneration. The institution besides posted mid- to high-single-digit maturation successful oncology, peripheral arterial illness and Rowa pharmacy automation.

→ Years successful the Making, AMD’s Upside Movement Has Just Begun

Executive Vice President and Chief Financial Officer Vitor Roque said Medical Essentials grew 1.7%, with coagulated U.S. maturation successful MDS and specimen management, partially offset by China marketplace dynamics. Connected Care grew 3.2%, led by precocious diligent monitoring, which accrued 12% connected spot successful U.S. consumables. Biopharma Systems declined 1.8%, arsenic double-digit biologics maturation led by GLP-1 products was much than offset by little vaccine demand.

Read Entire Article